Galmed Pharmaceuticals Ltd.
EOCNDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
Get an email about EOCN's next catalysts
Track Galmed Pharmaceuticals (EOCN) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming, 0 past
EOCN Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | FQ end Sep/2026 | Call: tbd
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
mFOLFOX6 + BIBF 1120 | Phase 2 | Colorectal Cancer | - | - |
Aramchol | Phase 2 | Non-Alcoholic Fatty Liver Disease | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Galmed Pharmaceuticals Ltd.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Galmed Pharmaceuticals Ltd.'s (EOCN) pipeline across Phase 2. Its lead program is Aramchol (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Galmed Pharmaceuticals Ltd.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Galmed Pharmaceuticals Ltd. (EOCN) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track EOCN biotech catalysts?→
Add EOCN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Galmed Pharmaceuticals Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.